Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

Creative Commons License

Colombel J., Panaccione R., Bossuyt P., Lukas M., Baert F., Vanasek T., ...Daha Fazla

LANCET, cilt.390, sa.10114, ss.2779-2789, 2017 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 390 Sayı: 10114
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1016/s0140-6736(17)32641-7
  • Dergi Adı: LANCET
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.2779-2789
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Bezmiâlem Vakıf Üniversitesi Adresli: Evet

Özet

Background Biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein, have been recommended for monitoring patients with Crohn's disease, but whether their use in treatment decisions improves outcomes is unknown. We aimed to compare endoscopic and clinical outcomes in patients with moderate to severe Crohn's disease who were managed with a tight control algorithm, using clinical symptoms and biomarkers, versus patients managed with a clinical management algorithm.